Copyright
©2014 Baishideng Publishing Group Inc.
World J Cardiol. Jul 26, 2014; 6(7): 653-662
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.653
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.653
Experimental system | Monitored response | Intracellular signal | Ref. |
Cultured cells | |||
NRG1 administration in neonatal cardiomyocytes | Sarcomeric F-actin polymerization | PI 3’-kinase | [16] |
Myofibrillogenesis - Growth | Ras-Mek-erk1/2 | [17] | |
Proliferation | PI 3’-kinase | [17] | |
NOS activation | [42] | ||
Muscarinic activation | [43] | ||
Karyo- cytokinesis | [44] | ||
NRG1 administration in human ESC | Specification of cardiomyocytes of the conduction lineage | [45] | |
Animal models | |||
NRG1b injection to ex vivo developing E12.5 dpc mouse | Differentiation of trabeculae | [17] | |
DNA synthesis, Proliferation | PI 3’-kinase | [17] | |
NRG1 administration in mouse with heart failure | Improved cardiac performance | [40] | |
Hypomorphic NRG1 deficiency in E8.5dpc mouse | Destabilization of gene regulatory network in the left ventricle | Erk1/2 | [39] |
Mouse ventricular-erbB2-KO | Overt dilation and reduced survival in erbb2 F/- postnatal mouse | [31] | |
Mouse ventricular-erbB2-KO | Dilation with cellular apoptosis | [32] | |
Mouse ventricular-erbB4-KO | Overt ventricular dilation at 3 mo and reduced survival | [33] | |
Lapatinib inhibition of erbB1/erbB2 in Mouse | erbB2-physiologic hypertrophy in pregnancy | MEK1/erk1/2 | [34] |
Adult ventricular-erbB4-KO | Cell division in myocardial infarction | [44] |
Experimental system | Monitored response | Ref. |
Cultured cardiomyocytes | ||
NRG-1 administration | Prevented myofibril disarray | [55] |
Attenuated troponin degradation | [56] | |
Animal models | ||
NRG1-deficiency/doxorubicin (NRG1 heterozygous mouse) | Induced heart failure | [57] |
NRG1-deficiency/doxorubicin (Ventricular specific-erbB4-KO) | Deregulated Protein Homeostasis Autophagic vacuolization | [58] |
Morphology | WT | KO | WTD | KOD |
Young adult (1 mo) | ||||
Heart/body weight (mg/g) | 5.2 ± 0.4 | 5.3 ± 0.6 | 5.2 ± 0.5 | 6.2 ± 0.8a |
Body weight (g) | 17.4 ± 2.0 | 17.3 ± 2.2 | 17.3 ± 2.0 | 17.2 ± 1.5 |
Adult (3 mo) | ||||
Heart/body weight (mg/g) | 5.6 ± 0.6 | 7.0 ± 0.8d | 5.4 ± 0.7 | 6.7 ± 0.8d |
Body weight (g) | 30.1 ± 2.5 | 30.3 ± 2.2 | 29.4 ± 2.2 | 28.4 ± 2.2 |
Cardiotoxic gene groups | ||||
Dilation (ratio) | - | 3 | 1.8 | 2.8 |
Hypertrophy (ratio) | - | 9.9 | 3.3 | 6.5 |
Damage (ratio) | - | 3.7 | 3.7 | 3.6 |
Cell death/ necrosis (Ratio) | - | 3.0 | 4.3 | 3.1 |
Measured activity | ||||
Caspase 3 (arbitrary units) | 0.25 ± 0.17 | 0.44 ± 0.17 | 0.84 ± 0.09a | 0.35 ± 0.07 |
Autophagic vacuolization (n°) | 0.07 ± 0.1 | 0.35 ± 0.3 | 0.2 ± 0.2 | 2.4 ± 2.1a |
Serum cTnI (mg/mL) | 0.15 ± 0.1 | 3.6 ± 1.5 | 0.7 ± 0.2 | 14.5 ± 4.2a |
LVDP (mmHg) | 109.2 ± 7.1 | 42 ± 8.2a | 94.5 ± 5.5 | 31.5 ± 5.4a |
Tau ½ | 37.4 ± 1.9 | 38.1 ± 4.9 | 36.1 ± 3.1 | 34.6 ± 2.9 |
- Citation: Vasti C, Hertig CM. Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines. World J Cardiol 2014; 6(7): 653-662
- URL: https://www.wjgnet.com/1949-8462/full/v6/i7/653.htm
- DOI: https://dx.doi.org/10.4330/wjc.v6.i7.653